- NCIt
- C7185
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (130)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients | recruiting | Phase 1 / Phase 2 | 91 | Curocell Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | recruiting | Phase 1 | 21 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| Combating Cancer-Related Fatigue: A Personalized Supportive Care Program |
| recruiting |
| N/A |
| 40 |
| UNC Lineberger Comprehensive Cancer CenterOTHER |
| 1 |
| Jul 1, 2026 |
| clinicaltrials |
| NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | recruiting | Phase 1 | 36 | C. Babis AndreadisOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma(EpiRev-NKT) | recruiting | Phase 1 / Phase 2 | 107 | Rong TaoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT06931652 | Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab(E-REVRI) | recruiting | Phase 2 | 60 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06132737 | [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients | recruiting | Phase 1 / Phase 2 | 15 | Pentixapharm AGINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07137494 | A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) | recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06271057 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | recruiting | Phase 2 | 65 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05625594 | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07350850 | A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL(PRIME-PCNSL) | recruiting | Phase 2 | 77 | Tongji HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05011045 | Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | recruiting | Phase 1 | 20 | Juan P. Alderuccio, MDOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07554898 | Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma | recruiting | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | recruiting | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03932279 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma | recruiting | — | 300 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05838599 | Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides | recruiting | Early Phase 1 | 25 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05366569 | Bio-CAR-T BS Study | recruiting | — | 45 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04613388 | Registry Study of Proton Radiotherapy in Lymphoma | recruiting | — | 200 | University Hospital HeidelbergOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05680558 | Photopheresis in Early-stage Mycosis Fungoides | recruiting | Phase 2 | 74 | Columbia UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04627753 | Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.(Lemon-C) | recruiting | Phase 2 | 30 | Kim, Seok JinOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07097363 | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 2 | 18 | University of WashingtonOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT03398161 | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | recruiting | Phase 2 | 44 | Jonathan BrammerOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03587844 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | recruiting | Phase 2 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07047885 | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | recruiting | Phase 1 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 248 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06026319 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | recruiting | Phase 1 | 24 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07473167 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients(TC011) | recruiting | Phase 1 / Phase 2 | 98 | TICAROS Co., Ltd.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05256641 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05934448 | Pembro Plus CAR T-cell Therapy in R/R in PMBCL | recruiting | Phase 2 | 35 | Jennifer Crombie, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05681195 | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | recruiting | Phase 2 | 15 | Baptist Health South FloridaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | recruiting | Phase 1 / Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07416890 | Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma | recruiting | Phase 2 | 24 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | recruiting | Phase 3 | 20 | Aldeyra Therapeutics, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2026source: clinicaltrials